GLP-1 RA and dual glucose insulinotropic polypeptide (GIP)/GLP-1 RA treatment in maturity-onset diabetes of the young (MODY): a descriptive case series
Authors' conclusion
GLP-1 RA and dual GIP/GLP-1 RA lowered HbA1c, BMI, and SU dose in patients with MODY.
Study context
- Population
- Individuals with MODY (4 HNF1A-MODY, 4 HNF4A-MODY, 1 ABCC8-MODY, 1 HNF1B-MODY) from two MODY cohorts who used GLP-1 RA or dual GIP/GLP-1 RA
- Participants
- 10 individuals
- Exposure
- Before vs after GLP-1 RA or dual GIP/GLP-1 RA therapy
- Outcome
- Change in HbA1c, BMI and SU dose before vs after therapy, HNF1A-MODY and HNF4A-MODY
Methodological detailsdescriptive, two MODY cohorts
- Descriptive
- Two MODY cohorts
Main finding
As reported in the abstract
- GLP-1 RA: HbA1c reduction (p=0.010)
- 1.3%
- GLP-1 RA: Body mass index (BMI) reduction (p=0.008)
- 2.90 kg/m²
- GLP-1 RA: total daily sulfonylurea (SU) dose reduction (p=0.005)
- 66.6%
- Dual GIP/GLP-1 RA: non-significant HbA1c decrease (p=0.104)
- 1.8%
- Dual GIP/GLP-1 RA: significant BMI reduction (p=0.010)
- 8.73 kg/m²
- Dual GIP/GLP-1 RA: all patients discontinued SU
- n=2
- Dual GIP/GLP-1 RA: discontinued insulin
- 1
Observational data: associations, not effects.
Further findings
GLP-1 RA in ABCC8-MODY and HNF1B-MODY
- HbA1c reduction, ABCC8-MODY and HNF1B-MODY, respectively
- 1.2% and 1.8%
- BMI reduction, ABCC8-MODY and HNF1B-MODY, respectively
- 1.1 kg/m² and 1.2 kg/m²
- No longer required SU (ABCC8-MODY) or insulin (HNF1B-MODY), respectively
Original publication
GLP-1 RA and dual GIP/GLP-1 RA treatment in MODY: a descriptive case series. BMJ Open Diabetes Res Care. Published 23 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →